Phase I trial of a melanoma vaccine with gp100280-288 peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes

Clinical Cancer Research

Volumn 7, Issue 10, 2001, Pages 3012-3024

  Slingluff, Craig L ^a,f   Yamshchikov, Galina ^a   Neese, Patrice ^a   Galavotti, Holly ^a   Eastham, Shannon ^a   Kittlesen, Dave ^a,g   Cohen, Roger ^b   Petroni, Gina ^c   Engelhard, Victor H ^a   Wiernasz, Catie ^d   Patterson, James W ^b   Conway, Brian P ^b   Ross, William G ^e   Grosh, William W ^e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Health Evaluation Sciences ^*  (United States)

^c Health Evaluation Sciences   (United States)

^d Cancer Center Clinical Trials Office   (United States)

^e Cancer Center FACS Core Facility   (United States)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYTOKINE; EPITOPE; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; MELANOMA VACCINE; MONTANIDE ISA 51; MONTANIDE QS 21; TETANUS ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FOLLOW UP; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LYMPH NODE METASTASIS; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TH1 CELL; TREATMENT PLANNING;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL LINE; CYTOKINES; EPITOPES, T-LYMPHOCYTE; FEMALE; FOLLOW-UP STUDIES; HEADACHE; HLA-A2 ANTIGEN; HUMANS; HYPERSENSITIVITY, DELAYED; INTERFERON TYPE II; LYMPH NODES; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASM STAGING; PAIN; PEPTIDE FRAGMENTS; SAPONINS; SKIN; SKIN DISEASES; SKIN TESTS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TETANUS TOXOID; TH1 CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034793424     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Melanoma vaccines
2. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
3. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
4. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100
5. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line
6. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro
7. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
8. Therapeutic vaccination against chronic viral infection: The importance of cooperation between CD4+ and CD8+ T cells
9. Delineation of several DR-restricted tetanus toxin T cell epitopes
10. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs
11. Universally immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells
12. Separation and characterization of saponins with adjuvant activity from Quillaja saponatria Molina cortex
13. Structural and immunological characterization of the vaccine adjuvant QS-21
14. Saponin adjuvant induction of ovalbumin specific CD8+ cytotoxic T-lymphocyte responses
15. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations
16. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients
17. Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
18. HLA-A2.1-associated peptides from a mutant cell line: A second pathway of antigen presentation
19. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
20. Shared epitopes for HLA-A3-restricted melanomareactive human CTL include a naturally processed epitope from Pmel-17/gp100
21. Localization of HLA-A2.1 restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum
22. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex
23. Analysis of a natural immune response against tumor antigens in a melanoma survivor: Lessons applicable to clinical trial evaluations
24. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
25. High- and low-dose interferon α-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
26. Pilot study of interferon alpha-2b tolerance in patients with stage III melanoma
27. Toxicity of adjuvant high-dose interferon-α-2b in patients with cutaneous melanoma at high risk of recurrence
28. Toxicity and feasibility of adjuvant high-dose interferon α-2b in patients with melanoma in clinical oncologic practice
29. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines
30. T cell memory. Long-term persistence of virus-specific cytotoxic T cells
31. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
32. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
33. Cytokine production, serum levels and disease activity in systemic lupus erythematosus
34. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-γ gene and protein expression in lupus T cells
35. Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients
36. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
37. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells